Christophe Schmitt

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg, Johnny Mahlangu, Benjamin Kim et al. · New England Journal of Medicine · 2017 · 1K citations · Full text

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Johnny Mahlangu, Johannes Oldenburg, Ido Paz‐Priel et al. · New England Journal of Medicine · 2018 · 708 citations · Full text

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Steven W. Pipe, Midori Shima, Michaela Lehle et al. · The Lancet Haematology · 2019 · 373 citations · Full text

Haven 4, Hematology, Non-randomised Phase 3 +2

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Guy Young, Ri Liesner, Tiffany Chang et al. · Blood · 2019 · 361 citations · Full text

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Juan P. Frías, Edward J. Bastyr, Louis Vignati et al. · Cell Metabolism · 2017 · 316 citations · Full text

Molecular Pharmacology, Metabolic Syndrome, Sustained Effects +9